To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:232 Issue:1 Number:1 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #14572
Ace Report Cover Arthroplasty

AAOS 2022: Oxidized Zirconium vs. Cobalt Chrome Femoral Heads in Total Hip Arthroplasty


How to Cite

OrthoEvidence. AAOS 2022: Oxidized Zirconium vs. Cobalt Chrome Femoral Heads in Total Hip Arthroplasty. ACE Report. 2022;232(1):1. Available from: https://myorthoevidence.com/AceReport/Report/14572

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Oxidized Zirconium vs. Cobalt Chrome Femoral Heads in Total Hip Arthroplasty: A Multicenter Prospective Randomized Controlled Trial with 10 Years Follow Up

Contributing Authors:
B Kayani J Baawa-Ameyaw A Fontalis J Tahmassebi N Wardle R Middleton FS Haddad

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

262 patients were assessed at the 10 year follow up of this randomized controlled trial comparing Oxidized Zirconium femoral heads with an ultra-high molecular weight polyethylene liner, Oxidized Zirconium femoral heads with a highly cross-linked polyethylene liner, and Cobalt Chrome femoral heads with a highly cross-linked polyethylene liner. Outcomes of interest included liner wear rate, inciden...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.